Telix jumps 2% on potential US listing

The news: Shares in Telix Pharmaceuticals have jumped 2% in early trading after the biopharmaceuticals play flagged a potential US listing. Telix is considering an initial public offering (IPO) of American depository shares and listing on the NASDAQ, while retaining its ASX listing.

The numbers: The number of ADSs and ordinary shares to be issued has not been determined, nor the price and the timing of their offering. TLX shares were trading 2.4% higher half an hour into the trading session, fetching $9.76.

The context: Telix has been on an expansionary path in recent months and recently announced plans to acquire Austin-headquartered radiopharmaceuticals developer QSAM Biosciences in an offer worth up to US123.1 million ($193.3 million). Any US listing would be subject to regulatory approvals.